Skip to main content

Table 1 Clinical pathological data of cervical SCC patients (n = 77)

From: Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer

Cervical SCC patients

Age (year)

Selection date

Clinical stage

Differentai-ation degree

Lymph node metastasis

Tumor size (cm)

LVSI

HPV infection

1

46

2010.7.2

Stage I

Well differentiation

No

≤ 4

No

Single/multiple HPV16 infection

2

44

2010.7.5

Stage II

Moderate and poor differentiation

No

≤ 4

No

Single/multiple HPV16 infection

3

35

2010.7.13

Stage I

Well differentiation

No

≤ 4

Yes

Negative

4

39

2010.7.26

Stage II

Moderate and poor differentiation

No

≤ 4

No

Negative

5

38

2010.7.30

Stage I

Moderate and poor differentiation

Yes

> 4

No

Other HPV type

6

30

2010.8.2

Stage I

Moderate and poor differentiation

No

≤ 4

No

Single/multiple HPV16 infection

7

47

2010.8.5

Stage III-IV

Well differentiation

Yes

≤ 4

No

Single/multiple HPV16 infection

8

41

2010.8.12

Stage II

Well differentiation

No

> 4

No

Single/multiple HPV16 infection

9

44

2010.8.23

Stage II

Moderate and poor differentiation

No

≤ 4

No

Negative

10

38

2010.8.23

Stage III-IV

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

11

27

2010.8.25

Stage III-IV

Well differentiation

No

≤ 4

No

Other HPV type

12

48

2010.8.30

Stage I

Moderate and poor differentiation

No

≤ 4

No

Negative

13

42

2010.9.7

Stage II

Well differentiation

Yes

> 4

Yes

Single/multiple HPV16 infection

14

44

2010.9.10

Stage I

Moderate and poor differentiation

No

≤ 4

No

Negative

15

42

2010.9.17

Stage I

Moderate and poor differentiation

No

> 4

No

Single/multiple HPV16 infection

16

45

2010.9.27

Stage II

Moderate and poor differentiation

No

> 4

No

Single/multiple HPV16 infection

17

44

2010.9.28

Stage II

Moderate and poor differentiation

No

1

No

Single/multiple HPV16 infection

18

42

2010.9.28

Stage II

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

19

47

2010.9.30

Stage II

Moderate and poor differentiation

Yes

> 4

No

Single/multiple HPV16 infection

20

39

2010.10.18

Stage I

Moderate and poor differentiation

No

≤ 4

No

Single/multiple HPV16 infection

21

48

2010.10.28

Stage II

Well differentiation

No

≤ 4

No

Single/multiple HPV16 infection

22

36

2010.11.2

Stage II

Moderate and poor differentiation

Yes

> 4

Yes

Other HPV type

23

43

2010.11.16

Stage II

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

24

34

2010.11.24

Stage I

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

25

46

2010.12.10

Stage III-IV

Well differentiation

---

> 4

---

Other HPV type

26

45

2010.12.16

Stage II

Well differentiation

---

≤ 4

---

Other HPV type

27

32

2010.12.27

Stage III-IV

Well differentiation

---

≤ 4

---

Single/multiple HPV16 infection

28

27

2011.1.7

Stage III-IV

Well differentiation

---

> 4

---

Single/multiple HPV16 infection

29

40

2011.1.14

Stage III-IV

Well differentiation

---

≤ 4

---

Single/multiple HPV16 infection

30

29

2011.1.17

Stage III-IV

Well differentiation

---

≤ 4

---

Other HPV type

31

42

2011.2.21

Stage I

Well differentiation

---

≤ 4

---

Single/multiple HPV16 infection

32

35

2011.2.25

Stage I

Well differentiation

---

≤ 4

---

Negative

33

29

2011.3.1

Stage III-IV

Well differentiation

---

> 4

---

Negative

34

38

2011.3.10

Stage III-IV

Well differentiation

---

≤ 4

---

Other HPV type

35

41

2011.3.15

Stage III-IV

Well differentiation

---

≤ 4

---

Single/multiple HPV16 infection

36

28

2011.3.19

Stage II

Moderate and poor differentiation

---

≤ 4

---

Single/multiple HPV16 infection

37

40

2011.3.21

Stage II

Moderate and poor differentiation

---

> 4

---

Negative

38

37

2011.4.9

Stage II

Moderate and poor differentiation

---

≤ 4

---

Other HPV type

39

43

2011.4.13

Stage II

Moderate and poor differentiation

---

> 4

---

Single/multiple HPV16 infection

40

29

2011.4.18

Stage II

Well differentiation

---

> 4

---

Other HPV type

41

43

2011.4.21

Stage II

Moderate and poor differentiation

---

> 4

---

Single/multiple HPV16 infection

42

53

2011.4.22

Stage III-IV

Moderate and poor differentiation

No

> 4

Yes

Negative

43

66

2011.5.10

Stage III-IV

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

44

54

2011.5.16

Stage III-IV

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

45

56

2011.5.23

Stage II

Moderate and poor differentiation

No

≤ 4

No

Other HPV type

46

57

2011.5.25

Stage II

Moderate and poor differentiation

Yes

≤ 4

Yes

Other HPV type

47

54

2011.5.30

Stage II

Well differentiation

No

≤ 4

No

Other HPV type

48

54

2011.6.3

Stage III-IV

Moderate and poor differentiation

Yes

≤ 4

No

Other HPV type

49

66

2011.6.10

Stage II

Moderate and poor differentiation

Yes

≤ 4

No

Other HPV type

50

77

2011.6.14

Stage III-IV

Moderate and poor differentiation

Yes

≤ 4

No

Single/multiple HPV16 infection

51

50

2011.6.15

Stage II

Well differentiation

No

≤ 4

No

Single/multiple HPV16 infection

52

68

2011.6.20

Stage II

Well differentiation

No

≤ 4

No

Negative

53

61

2011.7.11

Stage II

Moderate and poor differentiation

No

≤ 4

Yes

Negative

54

69

2011.7.15

Stage II

Moderate and poor differentiation

No

≤ 4

Yes

Other HPV type

55

49

2011.7.18

Stage II

Moderate and poor differentiation

No

> 4

No

Single/multiple HPV16 infection

56

49

2011.7.18

Stage II

Moderate and poor differentiation

Yes

> 4

Yes

Negative

57

54

2011.8.1

Stage II

Moderate and poor differentiation

No

≤ 4

No

Single/multiple HPV16 infection

58

51

2011.8.25

Stage III-IV

Well differentiation

No

≤ 4

No

Single/multiple HPV16 infection

59

56

2011.8.26

Stage II

Moderate and poor differentiation

Yes

≤ 4

Yes

Single/multiple HPV16 infection

60

53

2011.913

Stage II

Moderate and poor differentiation

No

> 4

No

Single/multiple HPV16 infection

61

50

2011.9.16

Stage I

Well differentiation

No

≤ 4

No

Other HPV type

62

51

2011.9.21

Stage II

Moderate and poor differentiation

No

≤ 4

No

Single/multiple HPV16 infection

63

49

2011.9.23

Stage I

Well differentiation

No

≤ 4

No

Negative

64

57

2011.10.14

Stage II

Moderate and poor differentiation

No

≤ 4

Yes

Negative

65

61

2011.11.2

Stage II

Well differentiation

No

> 4

No

Other HPV type

66

52

2011.11.15

Stage II

Moderate and poor differentiation

No

≤ 4

No

Negative

67

50

2011.11.17

Stage II

Moderate and poor differentiation

Yes

> 4

No

Single/multiple HPV16 infection

68

56

2011.11.21

Stage I

Moderate and poor differentiation

No

≤ 4

Yes

Negative

69

64

2011.11.25

Stage I

Moderate and poor differentiation

No

≤ 4

No

Single/multiple HPV16 infection

70

80

2011.12.2

Stage II

Moderate and poor differentiation

No

≤ 4

Yes

Single/multiple HPV16 infection

71

61

2011.12.2

Stage II

Well differentiation

Yes

≤ 4

No

Other HPV type

72

49

2011.12.5

Stage II

Moderate and poor differentiation

No

> 4

No

Other HPV type

73

49

2011.12.16

Stage II

Moderate and poor differentiation

Yes

≤ 4

No

Other HPV type

74

59

2012.1.10

Stage II

Moderate and poor differentiation

Yes

≤ 4

No

Other HPV type

75

50

2012.1.13

Stage II

Moderate and poor differentiation

Yes

> 4

No

Single/multiple HPV16 infection

76

67

2012.1.16

Stage I

Moderate and poor differentiation

No

≤ 4

Yes

Other HPV type

77

58

2012.1.19

Stage III-IV

Moderate and poor differentiation

---

≤ 4

---

Negative

  1. Note: SCC, squamous cell carcinoma; LVSI, lymph vascular space invasion. “---” indicates that no such examination was performed.
  2. Among the 77 cervical patients, 59 cases received extensive hysterectomy and pelvic lymphadenectomy and 18 cases were not treated with surgery. Lymph node metastasis and LVSI were not examined in these 18 cases who were not treated with surgery.